THE ECONOMICS OF ADJUNCTIVE THERAPIES IN CORONARY ANGIOPLASTY: DRUGS, DEVICES OR BOTH
Main Article Content
Keywords
abciximab, cost-effectiveness, percutaneous coronary intervention
Abstract
Oh and colleagues in Can J Clin Pharmacol Vol 11(2) Fall 2004:e202-e211; September 1, 2004 have provided a cost-effectiveness analysis (CEA) demonstrating that abciximab is more cost-effective than other commonly used therapies (for example, coronary artery stenting) and that it should be more universally used in PCI patients. The incremental cost-effectiveness ratio of $2,832 to $7,173 per life year gained with abciximab demonstrates greater value than almost any drug commonly used in cardiovascular medicine. Why then have physicians not routinely embraced abciximab?
References
2. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43.
3. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo- controlled trial. Lancet 2000; 356: 2037-44.
4. Kini A, Marmur JD, Kini S et al. Creatine kinase- MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to- medium level elevation has a benign clinical course : Implications for early discharge after coronary intervention. J Am Coll Cardiol 1999; 34:3:663-671.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.